Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ningjia Shen"'
Autor:
Hongyu Pan, Liuyu Zhou, Zhuo Cheng, Jin Zhang, Ningjia Shen, Hongbin Ma, Yao Li, Riming Jin, Weiping Zhou, Dong Wu, Wen Sun, Ruoyu Wang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) have dismal prognosis and there are no standard perioperative therapies. This phase 2 trial (ChiCTR2000036385) aimed to investigate the activity and safety of perioper
Externí odkaz:
https://doaj.org/article/accdca2c6f674bc290e498c74d942c41
Autor:
Lianghe Yu, Ningjia Shen, Yan Shi, Xintong Shi, Xiaohui Fu, Shuang Li, Bin Zhu, Wenlong Yu, Yongjie Zhang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundCancer-associated fibroblasts (CAFs) are involved in tumor growth, angiogenesis, metastasis, and resistance to therapy. We sought to explore the CAFs characteristics in hepatocellular carcinoma (HCC) and establish a CAF-based risk signature
Externí odkaz:
https://doaj.org/article/67001ea266bd44a2a642f2504688ab19
Autor:
Ningjia Shen, Bin Zhu, Wei Zhang, Baoning Nian, Xiaoya Xu, Lianghe Yu, Xiang Ruan, Sheng Chen, Yang Liu, Xinkai Cao, Xintong Shi, Zhikuan Li, Xingfeng Huang, Xiang Wang, Caifu Chen, Lei Xiong, Dadong Zhang, Xiaohui Fu, Yongjie Zhang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cell-free DNA (cfDNA) exists in various types of bodily fluids, including plasma, urine, bile, and others. Bile cfDNA could serve as a promising liquid biopsy for biliary tract cancer (BTC) patients, as bile directly contacts tumors in the biliary tr
Externí odkaz:
https://doaj.org/article/0608f6e89c254efea496d5c650882bb3
Autor:
Lei Yin, Ningjia Shen, Facai Yang, Anqi Duan, Bin Yi, Zhiyuan Bo, Yinghe Qiu, Bin Zhu, Jingdong Li, Zhaohui Tang
Publikováno v:
OncoTargets and Therapy. 13:2357-2367
Background Gallbladder cancer (GBC) is the most common cancer of the biliary tract, but molecularly targeted therapies are not available for GBC. Loss of microRNA (miR)-335 expression may be a useful predictor of clinical outcomes and the reversal of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b0ab50d19c2930bc17ae713d2ae108f
https://doi.org/10.2147/ott.s236350
https://doi.org/10.2147/ott.s236350
Autor:
Facai, Yang, Zhaohui, Tang, Anqi, Duan, Bin, Yi, Ningjia, Shen, Zhiyuan, Bo, Lei, Yin, Bin, Zhu, Yinghe, Qiu, Jingdong, Li
Publikováno v:
OncoTargets and therapy
Background Gallbladder cancer (GBC) is the most common cancer of the biliary tract, but molecularly targeted therapies are not available for GBC. Loss of microRNA (miR)-335 expression may be a useful predictor of clinical outcomes and the reversal of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59495409abfc5a2e83a36ecbee380d90
https://pubmed.ncbi.nlm.nih.gov/32256086
https://pubmed.ncbi.nlm.nih.gov/32256086
Autor:
Hao Qin, Jing‑Yu Li, Xiao-Hui Fu, Lei Xiong, Teng Zhao, Yongjie Zhang, Yinghe Qiu, Fugen Li, Wen-Long Yu, Xiang Wang, Liang-He Yu, Lei Yin, Zheng Fang, Xinkai Cao, Zishuo Chen, Dadong Zhang, Bin Zhu, Xiaoya Xu, Jian Liu, Zisong Zhou, Anqi Duan, Yuanjin Liu, Ningjia Shen, Bo Yuan
Publikováno v:
Oncology Reports
Tissue sampling of biliary tract carcinomas (BTCs) for molecular characterization is challenging. The aim of this study was to investigate the possibility of identifying individual actionable mutations derived from bile cell-free DNA (cfDNA) using ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e3b83ba4b74734b3b92948ce083173
https://doi.org/10.3892/or.2019.7177
https://doi.org/10.3892/or.2019.7177
Autor:
Ningjia Shen, Dadong Zhang, Lei Yin, Yinghe Qiu, Jian Liu, Wenlong Yu, Xiaohui Fu, Bin Zhu, Xiaoya Xu, Anqi Duan, Zishuo Chen, Xiang Wang, Xinkai Cao, Teng Zhao, Zisong Zhou, Lianghe Yu, Hao Qin, Zheng Fang, Jing-Yu Li, Yuanjin Liu, Lei Xiong, Bo Yuan, Fugen Li, Yongjie Zhang
Publikováno v:
Cancer Research. 79:2292-2292
Purpose: Biliary tract cancers (BTCs) are less common, but rapidly lethal tumors. Despite recent improvements in multimodal therapy, the 5-year survival rate is less than 10% in patients with advanced or metastatic BTC. BTC patients lack personalized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::084ff44d58d51a8a7b00470a15e0c453
https://doi.org/10.1158/1538-7445.am2019-2292
https://doi.org/10.1158/1538-7445.am2019-2292
Autor:
Jia Song, Yuzi Zhang, Jing Zhao, Xiao-Hui Fu, Shangli Cai, Wenlong Yu, Yongjie Zhang, Ningjia Shen
Publikováno v:
Journal of Clinical Oncology. 37:e15602-e15602
e15602 Background: Biliary tract cancers (BTCs) are aggressive malignancies associated with resistance to chemotherapy. Though immunotherapy presents a promising results based on several studies, the overall response rate is relative low. Tumor mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64fdbc2d81725a2c52c369f2957b4c3b
https://doi.org/10.1200/jco.2019.37.15_suppl.e15602
https://doi.org/10.1200/jco.2019.37.15_suppl.e15602
Publikováno v:
Hepato-gastroenterology. 61(130)
To evaluate the effect of vascular resection (VR) in surgical management of hilar cholangiocarcinoma (HCCA), this report did a clinical analysis and conducted a systematic review, combined other studies, based on meta-analysis.Two hundred and thirty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1b9fdfc24de51cdb834e9bb13c1aef9
https://pubmed.ncbi.nlm.nih.gov/24901130
https://pubmed.ncbi.nlm.nih.gov/24901130
Publikováno v:
Cell biochemistry and biophysics. 69(3)
To evaluate the effect of vascular resection (VR) in surgical management of hilar cholangiocarcinoma (HCCA), this report is used in a clinical analysis and conducted a systematic review, combined other studies, based on meta-analysis. 238 HCCA patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9246ecb46f0cddbf3c559d43a0ce2d
https://pubmed.ncbi.nlm.nih.gov/24510536
https://pubmed.ncbi.nlm.nih.gov/24510536